David Bond, MD

Management of relapsed or refractory disease is a highly relevant topic for patients with mantle cell lymphoma and the clinicians who treat them.

David Bond, MD, discusses 2 key findings from a recent study investigating the risk of developing a second cancer in patients with chronic lymphocytic leukemia treated with a BTK inhibitor.